Squamous Cell Carcinoma of Head and Neck Clinical Trials

38 recruitingLast updated: June 17, 2026

There are 38 actively recruiting squamous cell carcinoma of head and neck clinical trials across 28 countries. Studies span Phase 2, Phase 1, Not Applicable, Phase 3, Early Phase 1. Top locations include Boston, Massachusetts, United States, Lille, France, Madrid, Spain. Updated daily from ClinicalTrials.gov.


Squamous Cell Carcinoma of Head and Neck Trials at a Glance

38 actively recruiting trials for squamous cell carcinoma of head and neck are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 18 trials, with the heaviest enrollment activity in Boston, Lille, and Madrid. Lead sponsors running squamous cell carcinoma of head and neck studies include Janssen Research & Development, LLC, University Health Network, Toronto, and Brigham and Women's Hospital.

Browse squamous cell carcinoma of head and neck trials by phase

Treatments under study

About Squamous Cell Carcinoma of Head and Neck Clinical Trials

Looking for clinical trials for Squamous Cell Carcinoma of Head and Neck? There are currently 35 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Squamous Cell Carcinoma of Head and Neck trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Squamous Cell Carcinoma of Head and Neck clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 38 trials

Recruiting
Phase 2

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Squamous Cell Carcinoma of Head and Neck
Barbara Burtness50 enrolled1 locationNCT05317000
Recruiting
Phase 3

A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC500 enrolled186 locationsNCT07276399
Recruiting
Phase 1Phase 2

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

Squamous Cell Carcinoma of Head and Neck
Janssen Research & Development, LLC287 enrolled56 locationsNCT06385080
Recruiting
Phase 1

A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck
Johnson & Johnson Enterprise Innovation Inc.30 enrolled16 locationsNCT07219212
Recruiting
Phase 1Phase 2

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Cervical CancerUrothelial CarcinomaMelanoma+8 more
Bristol-Myers Squibb1,109 enrolled47 locationsNCT04895709
Recruiting
Phase 1

A Study of Sigvotatug Vedotin in Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckHER2 Negative Breast Neoplasms+9 more
Seagen, a wholly owned subsidiary of Pfizer1,006 enrolled159 locationsNCT04389632
Recruiting
Early Phase 1

Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy

Metastatic CancerHER2Locally Advanced Cancer+2 more
Vanderbilt-Ingram Cancer Center30 enrolled1 locationNCT06828588
Recruiting
Phase 1Phase 2

A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckOvarian Neoplasms+8 more
Cancer Research UK167 enrolled4 locationsNCT06380816
Recruiting
Phase 2

5-Fluorouracil Response and Optimization STudy (The FROST Trial)

Squamous Cell Carcinoma of Head and NeckMetastatic Squamous Cell CarcinomaRecurrent Squamous Cell Carcinoma of the Head and Neck
Washington University School of Medicine46 enrolled1 locationNCT07419464
Recruiting
Not Applicable

A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Squamous Cell Carcinoma of Head and Neck
The Second Affiliated Hospital of Hainan Medical University32 enrolled1 locationNCT07546383
Recruiting
Phase 1

Neoadjuvant CADI-05 in Combination With Pembrolizumab for Surgically Resectable Locally Advanced Head and Neck Squamous Cell Carcinomas

Squamous Cell Carcinoma of Head and Neck
Fox Chase Cancer Center22 enrolled2 locationsNCT07455032
Recruiting
Phase 2

Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence

Squamous Cell Carcinoma of Head and Neck
University of Arkansas100 enrolled6 locationsNCT05952934
Recruiting
Not Applicable

A Study of Head and Neck MRI and Tumor Microenvironment Biomarkers

Squamous Cell Carcinoma of Head and Neck
University Health Network, Toronto60 enrolled1 locationNCT06085781
Recruiting
Not Applicable

HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers

Squamous Cell Carcinoma of Head and Neck
University Health Network, Toronto40 enrolled1 locationNCT06487403
Recruiting
Phase 2

A Study of Sacituzumab Govitecan in Combination With Cetuximab in People With Head and Neck Squamous Cell Cancer (HNSCC)

Squamous Cell Carcinoma of Head and NeckOral Cavity CancerNasal Cavity Cancer+9 more
Memorial Sloan Kettering Cancer Center40 enrolled7 locationsNCT07063212
Recruiting
Phase 2

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

Squamous Cell Carcinoma of Head and Neck
Institut Claudius Regaud86 enrolled14 locationsNCT06557889
Recruiting
Phase 1

A Study of MGC026 in Participants With Advanced Solid Tumors

Breast CancerColorectal, CancerGastric Cancer+19 more
MacroGenics250 enrolled12 locationsNCT06242470
Recruiting
Phase 1Phase 2

Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors

Gastric CancerNon-small Cell Lung Cancer (NSCLC)Squamous Cell Carcinoma of Head and Neck+3 more
One-carbon Therapeutics AB43 enrolled4 locationsNCT07151040
Recruiting
Early Phase 1

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

Head and Neck CancerSquamous Cell Carcinoma of Head and NeckSalivary Gland Cancer+1 more
Brigham and Women's Hospital30 enrolled2 locationsNCT05553782
Recruiting
Phase 1

A Study of DM005 in Patients With Advanced Solid Tumors

Carcinoma, Non-Small Cell LungSquamous Cell Carcinoma of Head and NeckSolid Carcinoma
Doma Biopharmaceutical(Suzhou)Co., Ltd.136 enrolled6 locationsNCT06515990